Press Releases

Date Title
November 2, 2023
Outlook Therapeutics® Provides Update on Type A Meetings with FDA
ISELIN, N.J. , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that it has completed the requested Type
November 1, 2023
Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Live audio webcast fireside chat on Tuesday, November 7th at 1:50 PM ET ISELIN, N.J. , Nov. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of
September 29, 2023
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J. , Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that a Type A Meeting request has been
September 21, 2023
Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET ISELIN, N.J. , Sept. 21, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the
September 5, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Live video webcast presentation on Wednesday, September 13th at 9:30 AM ET ISELIN, N.J. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment
August 30, 2023
Outlook Therapeutics® Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
FDA issues Complete Response Letter (CRL) for ONS-5010 BLA based on CMC and need for further confirmatory clinical evidence Outlook Therapeutics working with FDA to address the Agency’s issues Company to host conference call and webcast, today, August 30 at 8:30 AM ET ISELIN, N.J. , Aug.
August 14, 2023
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) ISELIN, N.J. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
August 1, 2023
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
Live webcast fireside chat on Monday, August 7th at 1:00 PM ET ISELIN, N.J. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD,
May 15, 2023
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) Pre-launch commercial activities continue in preparation for potential approval and
April 27, 2023
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May 2nd at 2:00 PM ET ISELIN, N.J. , April 27, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
Displaying 21 - 30 of 207